Identifying robust biomarkers of infection

through an omics-based meta-analysis

Ashleigh C Myall[1,2], Simon Perkins[1], David Rushton[4], Jonathan David[5], Phillippa Spencer[6], Andrew R Jones[1,&], & Philipp Antczak[1,3,&]*

[1]Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom

[2]Department of Mathematics, Imperial College London, London, United Kingdom

[3]Center for Molecular Medicine, University of Cologne, Cologne, Germany

[4]Defence and Security Analysis Division, Defence Science and Technology laboratory (DSTL), Porton Down Salisbury, United Kingdom

[5]Chemical, Biological and Radiological Division, Defence Science and Technology laboratory (DSTL), Porton Down Salisbury, United Kingdom

[6]Cyber and Information Systems Division, Defence Science and Technology laboratory (DSTL), Porton Down, Salisbury, United Kingdom

*Corresponding author

E-mail: P.Antczak@liverpool.ac.uk (PA)

[&]Joint Senior Authors

Abstract

A fundamental problem for disease treatment is that while antibiotics are a powerful counter to bacteria, they are ineffective against viruses. To ensure a given individual receives optimal treatment given their disease state and to reduce over-prescription of antibiotics leading to antimicrobial resistance, the host response can be measured to distinguish between the two states. To establish a predictive biomarker panel of disease state we conducted a meta-analysis of human blood infection studies using Machine Learning (ML). We focused on publicly available gene expression data from two widely used platforms, Affymetrix and Illumina microarrays, and integrated over 2000 samples for each platform to develop optimal gene panels. On average our models predicted 80% of bacterial and 85% viral samples correctly by class of infection type. For our best performing model, identified with an evolutionary algorithm, 93% of bacterial and 89% of viral samples were classified correctly. To enable comparison between the two differing microarray platforms, we reverse engineered the underlying molecular regulatory network and overlay the identified models. This revealed that although the exact gene-level overlap between models generated from the two technologies was relatively low, both models contained genes in the same areas of the network, indicating that the same functional changes in host biology were being detected, providing further confidence in the robustness of our models. Specifically, this convergence was to pathways including the Type I interferon Signalling Pathway, Chemotaxis, Apoptotic Processes, and Inflammatory / Innate Response. Amongst and related to these pathways we found three genes, *IFI27, LY6E*, and *CD177*, particularly prevalent throughout our analysis.

Author summary

Bacterial and viral disease require specific treatments, and whilst there are various treatment options for specific infection types, rapid diagnosis and identification of the optimal treatment remains challenging. Even in wealthier countries with developed healthcare

systems, unnecessary prescription of antibiotics to patients with viral infections is causing

phenomena such as multi-drug resistent bacteria. One way to distinguish a viral from

bacterial infection is to measure an individual's responses, for example by measuring the

expression of particular genes in a blood sample, as different types of infections trigger

different types of responses. In our study we analysed thousands of previously collected data

sets from human blood, where individuals had either viral, bacterial or no infection (control).

We used machine learning to identify "signatures" – small sets of genes that are indicative of

the type of infection (if any) carried by an individual. Within data sets we used two different

technology platforms had been used to collect data. We demonstrated that their gene-level

signatures do not overlap perfectly when derived from the different platforms, the biological

networks from which those genes were derived, however, had a high overlap – giving

confidence that our models are robust against technology artefacts or bias. We have identified

a small set of genes that serve as strong biomarkers of infection status in humans.

Introduction

The varying differences within both classes of bacterial and viral infections cause the body to

respond in a distinct way (1). Bacteria can be countered by pathways such as complement-

mediated lysis, and the cell-mediated response for those that survive phagocytosis and live

within the cell (intracellular bacteria). In this response, cells present bacterial peptides

(antigens) on their surface, which are identifiable by Helper T cells that mediate bacterial

destruction (2). There are a large variety of viruses and bacteria that affect the host's immune

system in various ways. Whilst some response pathways may overlap for bacterial and viral

infections, there are however a number key differences (3, 4). In fact, these different response

pathways cause varied transcription (expression) of key genes and are the medium for

distinguishing disease state based on the host's transcriptional response (5).

Differential expression of certain genes related to immunological responses can be indicative

of both (i) disease state and (ii) individual pathogens (6). Such knowledge can be exploited in

differentiating between viral, bacterial and control biological states. Previous studies

demonstrated this by developing a small set of only seven genes that can accurately

discriminate bacterial from viral infections across a range of clinical conditions, whilst

simultaneously succeeding to determine with high accuracy which patients do not require

antibiotics (7). Simultaneously, there have been numerous other studies looking at diagnosing

infection based on the host's transcriptional response (8-12).

Previous work failed to generalise as the data contains a far smaller set of pathogens that

would be encountered in 'real world' scenarios, or studies focussed on single technology

platforms, specific pathogens, or geographical regions (which contain populations with

different HLA alleles, and different local pathogen groups). To address this lack of

generalisation this work aims to utilise a larger scale analysis over a more representative

sample set to improve biomarker generalisability. To gain statistical power and develop more

robust panels, meta analyses of publicly available data have proven to be an effective

technique (13). However, analysis integrating several cohorts together face inherent

limitations from systematic variations otherwise known as "batch effects". Without proper

handling, these batch effects have been shown detrimental in population level gene

expression analysis (14). Computational techniques exist to reduce batch to batch variation

(15). ComBat (16), used in our study, is a well-known batch correction algorithm, and has

been shown successful at removing batch effects between studies whilst retaining relatively

high amounts of the biological variation.

Data-driven identification of robust biomarkers is a much-debated subject in the biological

field. Several machine learning (ML) approaches have been proposed, with typically good

performance on data sets used in a given study, but poorer performance when biomarkers are

taken forward for validation. Important is the distinction between uni- and multi-variate

approaches to biomarker discovery. While identifying a single predictive marker might be

preferred in theory, multi-variate approaches have enabled the discovery of more complex

relationships that can provide performance (accuracy; sensitivity) far exceeding univariate

predictive models (17). One particular aspect in multi-variate predictive approaches is the

optimisation of the representative model, which rarely can be achieved through brute force

testing and relies on feature selection algorithms. In addition, models developed by ML

approaches provide a more complete understanding of the underlying biological mechanisms,

adding to our understanding of these systems. In this publication we focus on the use of the

Random Forest (RF) (18) classifier, which has been demonstrated to perform well in real-

world classification problems with high dimensionality and biased data (19). RFs are bagged

decision tree models, which classify data points on a subset of features and have been praised

for their ability to avoid overfitting (20). Unlike Support Vector Machines or Neural

Networks (two frequently used models with high predictive capabilities) RFs forego much of

the model selection step using an ensemble approach which builds many weak classifiers into

a single strong self-averaging, interpolating model (21). Whilst RFs consist of many weaker

models, they have been shown highly effective at capturing non-linear relationships between

model predictors and outputs in a number of genomic studies (22, 23).

In recent years bioinformatician seeking predictive models have been faced with increasingly

greater dimensionality to their data. With the needs of interpretable models many have

responded and used feature selection procedures, which aims to remove redundant and

irrelevant model features (24). The results of a smaller feature set not only offers improving

model performance, faster computational implementation, and greater interpretation of the

underlying generative process (25); but moreover lines up with the original pattern

recognition theory, that RFs, like many other ML models were not designed to cope with

large amounts of irrelevant features, often referred to as *the curse of dimensionality* (26). This

high dimensionality is especially pronounced in the case of gene expression data with the

total human gene set being ~20,000.

Various feature selection procedure exist and have been demonstrated in biological problems

(24). For this study we focused on Backwards Elimination (BW) (27) forming a well-

established benchmark, and an evolutionary algorithm, a more explorative and

parameterizable search approach, to obtain reduced model feature sets (17). BW essentially

searches for the optimal feature set by progressively eliminating the least important features

from a given dataset and testing whether the new model is significantly more accurate than

the previous. Whereas evolutionary algorithms are based on evolving population(s) of models,

which are repetitively intermixed, and subject to random point mutations. This evolutionary

process is assumed to produce converging model populations in terms of performance and

their associated feature sets (28).

The application of different computational pipelines often leads to different outcomes in

disease prediction (29). We believe, it is thus important not only to present performance

statistics for one given model generated by an ML pipeline, but to explore the underlying

biological response of a set of plausible models. By doing so, it is possible to develop a more

robust biomarker panel (mitigating overfitting which would generally produce models hard to

interpret biologically), and to understand why a given model, or set of similar models, are

valid.

In this work, we have performed a meta-analysis over publicly available transcriptomics data

(human blood samples where individuals had bacterial, viral or no infection), from two

microarray technologies (Affymetrix and Illumina). We applied feature selection and

machine learning for biomarker discovery and predictive model generation, and lastly we

explored the biological context of the resulting models by reverse engineering the underlying

networks. Representing omics data as a network, has several key benefits. One can often

better represent many complex systems as connected components, and the genome is no

exception (30). Clustering is one popular method to explore these complex networks and

many algorithms exist to reveal insight into these complex structure (31). Visualising a

clustered network allows us to explore aspects of this generative process, and how feature

selection unfolds over it. However, network construction can often be sensitive to the

computational approach and parameterization applied (32, 33). In our approach, we validated

our findings and mitigate any potential bias in network generation and clustering by

illustrating that the biological driven feature selection is consistent across two separate

networks, containing different studies, and derived from different technological platforms.

 Materials and Methods

Fig 1. Conceptual overview. Individual data (A), containing bacterial (b), viral (v), control (c), and samples with lower levels of study confidence (?s) is merged by common genes and pre-processed by Step 1. Step 1 outputs a combined and batch corrected dataset (B), where only b/v/c samples are present. Two instances of (B) are formed, one where samples of lower levels of support are integrated into b/v classes, and the other completely omitting uncertain samples. Feature selection is performed on data B in Step 2 using (i) Backwards Elimination, and (ii) an Evolutionary algorithm. Step 2's output is a number of Gene Lists (C) obtained in the feature selection. Data B is also used to infer and cluster a gene interaction network, by (i) reverse engineering the gene interaction network, and (ii) clustering the adjacency matrix. (D) is then formed as the clustered interaction network overlaid with genes found in the best performing mode of each dataset and search procedure.

To identify and validate a panel of biomarkers able to differentiate bacterial and viral

infections, we performed a meta-analysis of GEO gene expression data, all from open source

microarray human blood infection studies. Our analysis was divided into three major method

steps: i) pre-processing, ii) feature selection, and iii) inferring a gene interaction network, to

discover and our validate gene lists (Fig 1). Following the major steps, we performed and

report the results of a final out of sample test on data not previously used in the training phase

for greater validation.

Pre-processing

Data. Datasets from four technological platforms (two from Affymetrix platforms and two

from Illumina platforms), consisting of 3868 samples, from 21 different studies, were

included in the analysis (Table 1). These datasets were selected from a wider pool identified

in an initial scan of online databases, based on a variety of factors including: microarray

platform manufacturer (most prevalent platforms – Affymetrix and Illumina) and study set

size (larger studies with more predictive power), class pathogen strain distribution (aiming

for an equal distribution across the data); and ability to merge with other datasets in our

analysis.

Table 1. Summary of platform level Affymetrix and Illumina datasets prior to pre-processing.

Manufacturer	Platform (GPL)	Studies (GSE)	Distinct Genes	Sample Count (%)	Bacterial (b) (%)	Uncertain Bacterial (b?) (%)	Viral (v) (%)	Uncertain Viral (v?) (%)	Control (c) (%)	Other (%)
Affymetrix	GPL570	GSE49954, GSE50628, GSE54992, GSE25504, GSE66099, GSE69606, GSE6269, GSE18090, GSE28750, GSE34205	22,213	615 (100)	27 (4.4)	227 (36.9)	164 (26.7)	0 (0)	156 (25.4)	41 (6.7)
Affymetrix	GPL571	GSE52428, GSE95104, GSE17156	13,383	834 (100)	60 (7.2)	0 (0)	358 (42.9)	348 (41.7)	68 (8.2)	0 (0)

| Affymetrix | GPL9188 | GSE30550 | 13,383 | 268 (100) | 0 (0) | 0 (0) | 132 (49.3) | 119 (44.4) | 17 (6.3) | 0 (0) |
| Illumina | GPL10558 | GSE29385, GSE32707, GSE37250, GSE40396, GSE60244, GSE64456, GSE68310 | 19,947 | 2,151 (100) | 215 (10.0) | 141 (6.6) | 1069 (49.7) | 0 (0) | 467 (21.7) | 259 (12.0) |

Deduplicating genes by probes and merging datasets. Dataset columns (originally

microarray ProbeIDs) were first deduplicated and substituted by their gene mappings. Where

duplicate ProbeIDs existed for the same gene we selected a representative ProbeID with the

highest average intensity across samples (34). Samples from datasets of the same

manufacturer were then merged by common genes, first at the level of studies within the

same platform, then by platforms in the same manufacturer.

Batch correction and evaluation. Batch corrections targeted two non-biological sources of

systematic variation: (i) inter-platform study batch effects (differences between platforms),

and (ii) intra-platform batch effects (differences between studies within a batch). Batch

correction was implemented with 'ComBat' (16) in a two-step sequential batch correction

pipeline (S1 Appendix.docx). We repeated this process for both Affymetrix and Illumina

datasets separately to form batch corrected Affymetrix data, and batch corrected Illumina

data.

Batch correction was verified to retain biological variation and remove technical variation

using two validation steps (Fig 1 Step 1). Firstly, we tested whether pre and post batch

correction significant features overlapped significantly. Secondly, we performed Principle

Component Analysis (PCA) (35) visualising the data in two dimensions and comparing the

PCA plots of before and after batch correction. For a successful batch correction, pre-batch

correction sample clustering in the PCA would be visually removed in the PCA plot of post

batch corrected data.

Dealing with study sample ambiguity: forming a confirmed and integrated dataset

instance. To include more data, including some class ambiguity in the original studies, we

formed a modelling dataset which integrated bacterial and viral samples with lower levels of

confidence (b?, and v?)(Table 1). This integrated dataset contained only classes labeled b/v/c

(Fig 1). For Affymetrix this formed (Affy_I) and similarly, for Illumina this formed

Illumina_I. Two additional datasets of confirmed sample classes only, were also generated

and included in the study but presented only in the Appendix.

Feature Selection. To search for optimal panels of genes we implemented two search feature

selection procedures: (i) the well-known Backward Elimination process (27), and (ii) a

genetically inspired search algorithm (GALGO) (17). Both search procedures operated using

the RF Classifier, implemented in the R Ranger package (36) a fast and parallelisable

implementation of RFs for high dimensional data.

Dataset Preparation. For dealing with un-even class distributions present in our data (Table

1) we employed two strategies. Firstly, we used a study aware data split which insured

relatively equal class proportions across both training, test and evaluation data splits.

Secondly, we ensured that classification accuracy bias due to larger class proportion of

disease states was minimized by weighing smaller classes correspondingly higher (18). This

ensures that our model will not be biased to classifying samples with a larger proportion in

the dataset.

Backward Elimination. We operated on a 60/20/20 training/test/evaluation data split for

each dataset processed in BW (37). On each training set we ran 240 BW search procedures,

using Out-of-bag (OOB) error as the minimisation criterion and implementation using the

VarSelRF R package (38). Each run generated a single optimal model which minimised OOB.

For each dataset a single representative model was selected from the 240 runs which

maximised accuracy on test data.

Genetic-algorithm. The Genetic-Algorithm (GA) optimized approach is an efficient method

for creating suitable multivariate models. We used the R library GALGO (17) to identify a

small feature model by continuously crossing a number of small feature models

(chromosomes of features) with each other, hypothetically identifying better models with

successive generations. We used an initialised fitness goal of 0.95, model size (chromosome

size) of 15 genes, and k-fold cross-validation to counter overtraining. In the RF, larger classes,

namely viral, were also penalized, as to ensure equal predictions across classes. After 250

models, we generated a representative model through a frequency based forward selection

strategy which ensures only genes that contributed to predictions are included in the final

model (S2 Appendix).

Inferring underlying interaction network

We reverse engineered gene regulatory networks using ARACNe (39) which builds an

adjacency matrix of genes with their mutual information from expression data (Fig 1). These

networks allow identification of functional relationships between genes and their

corresponding products (40, 41). In addition, they can provide insight into the functionally

relevant groups of genes for distinguishing disease state, by examining locations of RF

selected genes.

To select significant interactions within our dataset we used a p-value threshold < 0.05 in the

ARACNe procedure. The approach can then estimate a mutual information threshold that is

relevant for the provided dataset and a specified p-value. With our data this resulted in a

threshold of MI > 0.0176 to be retained. From the gene pairs of mutual information, we

formed an edge table which was the basis for our interaction network. Nodes are genes and

edge weights are the mutual information between two genes, where greater mutual

information would suggest a stronger relationship. We then loaded our networks in

Cytoscape (42) which visualises molecular interaction networks and has support for a number

of clustering algorithms.

To identify highly interconnected sub-networks within our reconstructed regulatory network

we utilised the Cytoscape clustering plugin GLay (32). GLay uses an implementation of the

Girvan-Newman Edge-betweeness algorithm (43) which we used to split our networks it into

clusters of connected genes. This resulted in a number of smaller sub-networks and allowed

us to inspect their functional roles within the larger network. We then mapped higher level

ontologies, such as pathways and gene ontology from gene symbols and used the DAVID (44)

tool to provide enrichment analysis. The enrichment analysis looked at several different

ontologies, providing an indication of overrepresentation, which we used to infer the likely

biological function of a given cluster. Each cluster analysis generated an enrichment table

detailing enriched ontology terms along with enrichment ratios and (adjusted) p-values. From

the enrichment table we then produced a dotplot which depicted enrichment ratio, p-value

and gene count, along with a colour scheme denoting different ontologies, for visual

interpretation.

For clusters of genes with enriched and significant terms related to the immune response, we

labelled them manually as Functionally Relevant (FR) clusters. These FR clusters allowed us

to make inferences about which biological functions hold predictive power, by overlaying

model selected genes onto our labelled gene regulatory network.

Out of sample testing

Out of sample testing usually refers to testing a model on data not previously seen in model

training and selection (37). Whilst a validation set was held back for both Affymetrix and

Illumina data, the validation data still contained samples from the same manufacturer and

group of studies used in training. Hence, within the original 'discovery dataset', gene lists

could still be overfit to some non-biological effect persisting in either the manufacturer

technology or set of studies present, which was not removed by batch correction.

To properly test generalisability and investigate any discovery data bias, we evaluated the

best performing models discovered on both Affymetrix and Illumina data by retraining and

testing them on non-discovery data (Affymetrix Gene Lists to Illumina Data, and Illumina

Gene lists to Affymetrix Data). These non-discovery datasets contained samples from

different studies and technology and therefore represented the ideal validation datasets. With

similar error between discovery and non-discovery data one can be confident that models

have not overfitted to a given dataset and are suggested to be generalisable.

Results

Pre-processing

Gene de-duplication and data merging was successful for both Affymetrix and Illumina. In

the final Illumina datasets 19,947 distinct genes were found intersecting all studies, whereas

for Affymetrix Data we found 13,383 (Table 2). This lower Affymetrix count was due to

platforms GPL571 and GPL9188 having only 13,383 distinct genes (**Table 1**). This gene loss

from intersection resulted in the omittance of 8,830 gene columns, which were present for the

615 samples in GPL570.

Affymetrix platforms were successfully merged and combined via our batch correction

pipeline, indicated by non-significant changes in differentially expressed (DE) genes and

removal of clustering in our PCA analysis between both study and platform batch corrections

(S1 Appendix). Illumina based datasets were represented by a single platform, GPL10558.

Batch correction did not result in significant changes to DE genes and removed the

previously observed clustering by study (S Fig 2).

This resulting two datasets Affy_I and Illumina_I contained 1676 and 1892 samples

respectively (**Error! Reference source not found.**). It is evident there is an uneven class

distribution present in both datasets. Both Affy_I and Illumina_I are made up of more than 50%

viral samples (66.89% and 56.50%, Table 2). The most underrepresented class is bacterial

samples, with both datasets comprising fewer than 20% samples labelled as bacterial (Table

2).

Table 2. Merged and batch corrected modelling dataset description. Merged and batch corrected

Affymetrix and Illumina (ambiguous classes integrated) dataset breakdown by distinct genes,

platforms, class make up, and sample count.

Dataset	Distinct Genes	Platforms	Bacterial Samples	Viral Samples	Control Samples	Total Samples
Affy_I	13,383	GPL570 GPL571 GPL9188	314 (18.74%)	1121 (66.89%)	241 (14.38%)	1676
Illumina_I	19,947	GPL10558	356 (18.82%)	1069 (56.50%)	467 (24.68%)	1892

Biomarker lists

Running GA and BW on both Affymetrix and Illumina generated an ensemble of models for

each method-datasets pair. For BW this was an ensemble of optimal models, one per run of

the algorithm. For GA this was the evolved chromosomes obtained by repeats of the search

procedure. From this ensemble of models, we computed relative gene selection frequencies

(top 16 genes displayed Table 3).

Table 3. Top 16 Gene selection for Affymetrix and Illumina models and their relative selection

frequencies. Frequency provided in brackets is based on the model selection frequency in each

optimisation run (the number of times a gene was selected across the number of optimised models).

Bold genes are included amongst 3 of models top 16 selection, and underlined genes are included in

all four.

Affymetrix Genes (relative frequency)		Illumina (relative frequency)	
BW	GA	BW	GA
MS4A4A (1.00)	PCOLCE2 (1.00)	**IFI44** (1.00)	**IFI27** (1.00)
MTHFD2 (1.00)	CEP55 (0.97)	MCEMP1 (1.00)	EPSTI1 (0.41)
RSL24D1 (1.00)	HBA1.HBA2 (0.88)	CD177 (1.00)	<u>**LY6E**</u> (0.39)
TSPO (1.00)	CDC27 (0.66)	GPR84 (1.00)	SPATS2L (0.34)
<u>**LY6E**</u> (1.00)	TSPO (0.56)	EIF1 (1.00)	RSAD2 (0.26)
MMP8 (1.00)	<u>**LY6E**</u> (0.50)	**IFI27** (1.00)	IFIT5 (0.24)
NSUN7 (1.00)	MMP8 (0.47)	EPSTI1 (1.00)	**IFI44** (0.24)
IFI27 (1.00)	PGD (0.47)	REPIN1 (1.00)	ZDHHC19 (0.22)
CXCL10 (1.00)	RSL24D1 (0.47)	<u>**LY6E**</u> (1.00)	FCGR1A;FCGR1CP (0.21)
ITGAM (1.00)	SIGLEC1 (0.47)	ALKBH5 (1.00)	IFI44L (0.19)
PSMA6;KIAA0391 (1.00)	**IFI44** (0.44)	EEF2 (1.00)	MCEMP1 (0.19)
GRB10 (1.00)	OAS3 (0.44)	RBM33 (1.00)	PRC1 (0.18)
GYG1 (1.00)	WNT10B (0.44)	ARRB1 (0.99)	HPGD (0.17)
PGD (1.00)	ADAMTS3 (0.41)	DSCR3 (0.99)	OAS2 (0.17)
CD177 (0.99)	HPR.HP (0.38)	TSPAN18 (0.99)	HERC5 (0.17)
OLAH (0.99)	OLAH (0.38)	FCGR1A;FCGR1CP (0.96)	IFITM3 (0.15)

BW search procedures in both technologies converged to a small set of genes, indicated by

high relative selection rate calculated by the number of times a gene was selected across the

multiple runs performed in each optimisation procedure. For Affymetrix 14 were included at

a rate of 1.0, whereas for Illumina BW results contain 12 genes at a rate of 1.0 (Table 3).

GA's on the other hand contained a much wider gene selection in the evolved chromosome,

in both search procedures only a single gene was included at a relative rate of 1.0. which

reflects the more varied selection in GA search procedures.

Overall search results (aggregated between runs by frequency) from BW and GA in both

Affymetrix and Illumina all contained *LY6E* (Lymphocyte antigen 6E, UniProt: Q16553)

amongst their 9 most frequently selected genes (Table 3). Amongst the next widely selected

genes were *IFI27* (Interferon alpha-inducible protein 27, mitochondrial, UniProt: P40305)

and *IFI44* (Interferon-induced protein 44, UniProt: Q8TCB0), both in the top 16 by gene

selection frequency for three of the four search procedures (Table 3). These 3 genes (*LY6E,*

IFI27, and *IFI44*) are all type-I interferon-inducible genes (ISGs), demonstrated to have

altered expressions in disease states, and known to be highly effective at countering infection

(45-48). Furthermore, an additional number of other ISGs were also found amongst the

frequently selected model genes (*MS4A4A, IFI44L, OAS2, and IFIT5*).

Additionally, several other most frequently selected genes have been linked to certain disease

states in the literature. Particularly increased levels of *MMP8* have been observed in HIV-

infected patients, which cross-references well as a high proportion of samples in our

modelling data coming from HIV viral studies (49). *SIGLEC1* is a Type I transmembrane

protein expressed by a subpopulation of macrophages and was one of fifteen genes found

upregulated during *in vivo* respiratory syncytial virus infections (50), whilst also said to

initiate the formation of the virus-containing compartment (51).

Fig 2. Gene frequency in Affymetrix and Illumina models. Each Model frequency is scaled between 1 and 25. Model overlapping gene

frequencies are then stacked and coloured by model-dataset combination. Affymetrix Models by shades of blue and Illumina models by shades of

red.

To further investigate gene convergence, we compared the relative model gene inclusion

rates for all search procedures together. We scaled each model gene frequency (between 1

and 25), then plotted them together as a stacked bar plot. Fig 2 shows the resulting stacked

frequency, where genes are visualised for greater than 5% aggregated inclusion across all

search procedures. Similarly, to our top 16 gene comparison, *LY6E* is indicated as important,

being represented in all search procedures. However, interestingly *IFI27* is also included

amongst all search procedures. Furthermore *CD177*, a neutrophil-specific receptor and

known to be at increased expression for patients in septic shock (52, 53), was selected

relatively frequently and present in all search procedures.

One interesting aspect to look at is the intersection of this between Genes frequently selected

between Affymetrix and Illumina generated models. We identified 88 genes intersecting

between Affymetrix and Illumina (S1 Table) and performed functional enrichment analysis

of them using DAVID. We found both highly enriched and significant terms relating to the

immune response. Included in the list of significant pathways was, in order of significance

Fig 3. Functional enrichment analysis of the identified 88 genes intersecting between Affymetrix

and Illumina search procedures. 'Antiviral defense' is the most significant term, whilst 'type I

'Antiviral defense' comprising of 12 genes, the 'type I interferon signalling pathway' which

included 10 genes, and 'Immunity' encompassing 17 of the 88 genes intersecting between

Affymetrix and Illumina search procedures (**Fig 3**).

For each search procedure we obtained a final representative model (Affy_BW, Affy_GA,

Illumina_BW, and Illumina_GA) and evaluated its performance on a held-out data split.

Model performance was recorded as the size of the gene list and its class-based performance

in terms of: Balanced Accuracy, Sensitivity, Specificity, and Mcnemar's Test p-value which

tests for consistency in responses and can reveal bias to classifying a certain class (all metrics

derived from the evaluation data split) (54).

Table 4. Overall optimal model performance. Model performance break down by Affymetrix and

Illumina data sets on the held out test dataset in terms of final model gene size, Balanced Accuracy,

Sensitivity, Specificity, and Mcnemar's Test p-value

	Model-Dataset Combination	Gene-set Size	Balanced Accuracy (B/C/V)	Sensitivity (B/C/V)	Specificity (B/C/V)	Mcnemar's Test p-value
Affymetrix Identified Models	BW	33	0.94 / 0.78 / 0.86	0.90 / 0.57 / 0.97	0.93 / 0.96 / 0.76	3.57e-3
	GA	36	0.93 / 0.82 / 0.89	0.88 / 0.66 / 0.97	0.99 / 0.97 / 0.81	4.90e-10
Illumina Identified Models	BW	30	0.86 / 0.70 / 0.78	0.80 / 0.47 / 0.87	0.93 / 0.92 / 0.87	2.36e-3
	GA	37	0.82 / 0.58/ 0.89	0.83 / 0.58 / 0.89	0.93 / 0.94 / 0.77	4.33e-15
Average	Average	34	0.89 / 0.72 /	0.85 / 0.57 /	0.95 / 0.95 /	5.93e-3

			0.86	0.93	0.80	

Average model size was similar between both Affymetrix and Illumina models (30-37 genes)

(Table 4). On average models classified 0.89 of Bacterial, 0.72 of Control and 0.86 of Viral

classes correctly across all datasets. In particular, the Affymetrix models, BW and GA,

performed particularly well in terms of balanced accuracy on bacterial samples (0.94 and

0.93 respectively). In terms of sensitivity all models performed well for bacterial and viral

classes (on average 0.85, and 0.93 respectively), however control sample performance was

worse when compared to the viral and bacterial classes (0.57). Evaluating model specificity,

bacterial performance was particularly high over all models (averaging 0.95) which would

suggest we can determine what a bacterial sample is particularly well regardless of the model

used (Table 4).

Inferred interaction networks

We inferred the underlying gene regulatory networks for both Affymetrix and Illumina

Fig 4. Clustered Illumina interaction network. Illumina models' selected genes are blue,

Affymetrix selected genes are orange, and those intersecting both technologies are pink. (A) Illumina

Interaction network after initial clustering (visualising clusters > 10 Genes). (B) Cluster 3, containing

the most selected genes which intersected between Affymetrix and Illumina models. (B.1) Cluster 3

Enlarged. (C) Highly selected sub clusters of Cluster 3. (D) Cluster 3.4, a sub cluster of Cluster 3

containing two genes which were selected by both Affymetrix and Illumina models.

datasets, but present here the analysis on the larger Illumina network (Affymetrix analysis in

S3 Appendix). GLay clustering of the gene interaction network initially revealed 14 clusters

containing more than 10 genes (Fig 4). To enable a more granular analysis of specific

network sections (those indicated to be functionally relevant in the immune response (FR) as

indicated by enrichment analysis, or containing genes selected by our models) we further

partitioned several of the initial clusters, forming a network hierarchy (limited to a depth of 3).

This resulted in 110 distinct groups of genes which we analysed (Table 5).

In Illumina 24 of the 110 clusters had enriched and significant terms related to functions of

the immune system in our DAVID analysis (Table 5). Of these 24 FR clusters, 10 had at been

selected by at least one Illumina model. These 10 clusters contained 55 genes in the union of

Illumina models (68% of all 81 Illumina selected genes in the network). Additionally, a small

number of clusters (four) were selected by every model.

Table 5. Illumina interpreted inferred interaction network properties. Clusters have been labelled

either functionally related to the immune response (FR). For a cluster to be labelled as FR, functional

enrichment analysis of their gene list will have revealed terms both enriched and significant

implicated in the host response to disease.

Manufac turer	Nodes (Genes)	Sub-clusters of more than 4 Genes	FR Clusters (% of all)	FR Clusters selected by > 1 Model (% of all)	FR Clusters selected by all four Models (% of all)
Illumina	19839	110 (1.00)	24 (21)	10 (9)	4 (4)

Affymetrix – Illumina cluster comparison. We found a similar number of clusters

converged to between both Affymetrix and Illumina gene lists in their respective networks

(S3 Appendix). It is clear the RF models are selecting genes from multiple of these

uncorrelated clusters, to build a stronger, less correlated model feature sets able to define

disease state. For greater biological understanding we compared the most selected clusters

from both the Affymetrix and Illumina Interaction Network. In Illumina this was Cluster

3.1.3 (S3 Appendix). Whilst the size between both clusters was not comparable (Affymetrix –

Cluster 5 being 435 Genes and Illumina Cluster 3.1.3 being only 47) we found an intersection

of 16 Genes (*DDX60, IFI35, IFI44, IFI44L, IFIH1, IFIT1, IFIT2, IRF7, ISG15, MX1, OAS2,*

SCO2, TIMM10, TRAFD1, TRIM22 and ZBP1) which was statistically significant (p-value <

3.18e-12), 10 of which known to be ISGs (*IFI35, IFI44, IFI44L, IFIH1, IFIT1, IFIT2, IRF7,*

ISG15, MX1, OAS2) (47). Performing DAVID enrichment analysis on both clusters, we find

in Illumina Cluster 3.1.3 one highly enriched term 'type I interferon signalling pathway'

albeit with a non-significant p-value (S3 Appendix). We do not see the same term in the

Affymetrix cluster; however, it does contain numerous ISGs, which we saw commonly

amongst gene lists. This convergence between independent feature selection across separate

manufacturers and different studies reinforces the high predictive power of ISGs for

discriminating disease state across infection studies.

Independent cluster convergence between Affymetrix and Illumina models. To examine

whether convergence between Affymetrix and Illumina was also to the same clusters

containing the same genes we looked at where in the Illumina interaction network Affymetrix

gene lists selected from (Fig 4, full break down in S3 Appendix). Although selected genes

varied between Affymetrix and Illumina, we indeed found that both converged around the

same clusters of genes. Moreover, we found that 19 clusters (including lower level sub

clusters) were selected by both Affymetrix and Illumina models in the Illumina interaction

network. Interestingly amongst this set, the four sub clusters intersecting across all Illumina

gene lists (all from within the larger Illumina-Cluster 3: Fig 4) were also selected by

Affymetrix gene lists: Illumina-Cluster 3.1.3, Illumina-Cluster 3.1.4, Illumina-Cluster 3.1.5,

and Illumina-Cluster 3.4. All of these clusters contained genes revealed by selection

frequency analysis in previous section 4.2.

We investigated all four clusters selected by all Illumina models (Clusters 3.1.3, 3.1.4, 3.1.5

and 3.4) and found they could be separated functionally to different aspects of an immune

response. As mentioned, enrichment analysis on Illumina Cluster 3.1.3 revealed the ISGs to

be present. However, enrichment analysis also revealed a number of both highly enriched and

significant terms related to viral infections ('response to Viruses', 'defense response to

virus'), and most prominently 'Antiviral Defense' which is no surprise given the high number

of interferon related genes in the cluster (S3 Appendix). Comparing the 47 genes in Clusters

3.1.3 to our model frequency analysis revealed 18 overlapping genes (*DHX58, EPSTI1,*

HERC5, IFI44, IFI44L, IFI6, IFIT1, IFIT2, IFIT5, ISG15, MX1, OAS2, OAS3, RSAD2, RTP4,

SAMD9, SPATS2L, and TMEM123).

For cluster 3.1.4, in which *LY6E* resides, it bears relation to cell signalling with by far the

most significant and enriched term 'chemotaxis' (S3 Appendix). Chemotaxis is well known

to play critical role in host response to infections, and is specifically involved in recruitment

of leukocytes, and movement of lymphocytes around the body (55). The intersect of cluster

3.1.4 with our model frequency analysis was also large, being 12 of its 40 genes *(ATF3,*

CCL2, CXCL10, HERC6, LAMP3, LGALS3BP, LY6E, OTOF, PARP12, SEPT4, SERPING1,

and SIGLEC1).

Cluster 3.1.5 contains genes involved in programmed cell death, containing several

significant and enriched terms like 'Apoptosis', 'Regulation of apoptotic process' and

'apoptotic process' (S3 Appendix). A total of 3 of its 37 genes intersected our model

frequency analysis (*CHMP5, FCGR1A, and FCGR1B*).

Illumina cluster 3.4 contained genes more related to general innate responses with enriched

terms containing 'Inflammatory response' and 'innate immune response' with non-significant

p-values (S3 Appendix). Amongst the genes are a number related to the Toll-like receptor

family (also an enriched and significant term), which respond to microbial products and

viruses, and are key-receptors of the innate immune system (56). Although not visible in the

functional enrichment analysis, Illumina Cluster 3.4 also contained a number of Interleukin

genes (*IL1B, IL1R1, IL4R, IL18R1, IRAK3*), known to be involved in inflammation and

fundamental to innate immunity (57). Out of the 253 genes in cluster 3.4, 15, including

CD177, intersected with previous frequency analysis (*BATF, CD177, DDAH2, GADD45A,*

GPR84, GRB10, GYG1, HK3, IRAK3, MAN2A2, MKNK1, NSUN7, SULT1B1, TSPO, and

ZDHHC19).

Cross manufacturer gene list performance

We evaluated each of the BW & GA representative models from Affymetrix on the Illumina

Data and Illumina Models on the Affymetrix data. Contrasting each model's performance

between these two discovery and non-discovery datasets we get the performance results

depicted in Fig 5. This figure shows the difference between overall accuracy, and class-based

accuracy, speciality and sensitivity when generalising our models to data pertaining from a

different technology and set of studies.

In terms of overall accuracy (Fig 5 A) Affymetrix models, both GA ad BW, performed worse

when applying to the Illumina data. However, the drop was less than 0.1 for both Affymetrix

Fig 5. Cross manufacturer model change in performance. Difference in performance when taking
Affymetrix derived models and testing on the Illumina data, and the Illumina derived models when
testing on the Affymetrix data. (A) Difference in performance in terms of overall Accuracy. (B) Class
based performance in terms of Balanced Accuracy, Sensitivity, and Specificity. For each performance
measure, bars are grouped by model, and each bar refers to the difference between performance on the
original dataset (which each model was discovered on) and the performance on the data it had not
been exposed too. For Affymetrix models this would contrast the performance on the Affymetrix data,
with the same model's performance on the Illumina data.

GA and BW. Whereas for Illumina, both GA and BW models slightly gained accuracy when

applied to the Affymetrix data (0.04 and 0.05 respectively).

Looking specifically at bacterial performance (Fig 5 B), both Illumina models performed

worse on the Affymetrix data in terms of bacterial balanced Accuracy (BW_I 0.71 and GA_I

0.73 2dp). Whereas the Affymetrix models performed well on the Illumina data (BW_I 0.89

and GA_I 0.89 2dp). In terms of bacterial specificity there was little change for all models,

staying within +/- 0.05 2dp of change in performance. However, in terms of bacterial

sensitivity, the Illumina models performed particularly worse on the Affymetrix data (BW_I

0.44 and GA_I 0.47 2dp).

Across viral class specific metrics (Fig 5 B), no model had any large change in Balanced

Accuracy (change < 0.05 2dp). The largest metric change was seen in sensitivity, with

Affymetrix models slightly decreasing, but with an original score of 0.97 and 0.95 for BW_I

and GA_I they are still performing well when ran on the Illumina data.

Overall, both Affymetrix and Illumina models performed well given that data was pertaining

from different manufacturers and different groups of studies. Particularly stability around

viral performance suggests a robustness to the gene lists for classifying viral samples

correctly. However, given that bacterial performance change was very comparable to viral, it

too suggests a strong ability to classify bacterial samples, even when moving out of the

original dataset.

Discussion

Discussion

Due to the amount of relevant data, we focused our analysis on studies from two of the

largest microarray platforms, Affymetrix and Illumina. Whilst these both determine the

expression levels of genes and are common in large-scale population studies, differences in

quantification and normalisation of gene expression values create technical difference (58).

Studies within manufacturers were successfully batch corrected, indicated by non-significant

changes in differentially expressed genes and removal of sample clustering by studies and

platforms in PCA analysis. However, the combination of studies between manufacturers was

unsuccessful, leading to two parallel analyses on the combined and batch corrected versions

of (i) Affymetrix and (ii) Illumina datasets which minimized biological variation loss.

Simpler solutions are more specifically justifiable and allow for greater interpretation, which

is the motivation for feature selection amongst models in biological data. We employed two

feature selection algorithms using the Random Forest Classifier over our Data: Backwards

Elimination and GALGO – both essentially cutting the noise and finding the most significant

biological variation responsible for predicting disease state. It is unknown without a brute

force search whether a *truly* optimal combination of genes has been found, however both BW

and GA approaches converged around a small group of genes located in uncorrelated and

functionally separable clusters. Models were found to be strongly enriched for the ISGs. In

fact, *IFI27* and *LY6E* (both ISGs) were included in all Affymetrix and Illumina models. *IFI27*

is involved in various signalling pathways affecting apoptosis (59-61). Whereas, *LY6E*

belongs to a class of interferon-inducible factors that broadly enhance viral infectivity (62).

LY6E has also been attributed a diverse set of effects, including attenuating T-cell receptor

signalling (63) and suppressing responsiveness to *Lipopolysaccharide* which stimulate

immune responses (64). Moreover, *IFI27* was shown by Tang et al. to be a *single–gene*

biomarker that discriminates between influenza, and other viral and bacterial infections in

patients with suspected respiratory infection (65). However, this single-gene biomarker

approach lacks generalisability and robustness when predicting a more varied pathogen set.

As we have observed, performance in our meta-analysis was greatly improved by including

more genes in our models.

Our larger set of RF selected genes contained numerous examples confirmed by previous

studies to be implicated in disease states. For instance, our results coincide with recent meta-

analysis, by Andres-Terre et al., looking at transcriptional signatures of infections,

specifically in distinguishing influenza from other viral and bacterial infections, which found

127 multi-gene signatures, 27 of which were also present in our representative models (*ATF3,*

BST2, CXCL10, EIF2AK2, HERC5, HERC6, IFI27, IFI44, IFI44L, IFI6, IFIT1, IFIT2, IFIT5,

ISG15, JUP, LGALS3BP, LY6E, MRPL44, MTHFD2, MX1, OAS1, OAS2, OAS3, OASL,

RSAD2, RTP4, SERPING1, SPATS2L) serving to validate our successful data integration and

biological findings (66). Notably amongst these coinciding genes are *IFI27* and *LY6E,* again

confirming the validity of our converging feature selection.

By inferring the underlying interaction network, we discovered that convergence was not

only happening to a set of genes, but also, and more prominently, convergence was focusing

around particular groups of functionally similar genes. This gene-group convergence only

emerged as part of an in-depth investigation into the driving forces of feature selection from a

biological network perspective. When representative members of these uncorrelated gene

clusters are taken together, they can form highly predictive gene lists. With the ability to

define the host response to viral and bacterial infections, genes of our identified clusters are

likely good at approximating key functions important in disease state prediction. Notably, the

four functional groups of genes were indicated to be: Type I interferon-inducible genes

(ISGs), Chemotaxis genes, Apoptotic Processes genes, and Inflammatory / Innate Response

genes, which were prevalent in every model (both Affymetrix and Illumina). Within this

cluster convergence we found a highly selected group of genes to be ISGs (the most frequent

between both Affymetrix and Illumina models). This is no surprise, given Type I Interferons

serve as a link between the innate and adaptive immune systems (67) and have a broad range

of effects on both innate and adaptive immune cells during infection with viruses, bacteria,

and parasites (47). Their varying sensitivity to particular forms of pathogens is likely why a

number can be used in conjunction for classification with RFs. While ISGs exact function are

not fully understood, it appears our RF models have identified their strong connection to

disease state (68, 69). Whilst convergence was prominent around four functional groups of

genes, we also note that both in Affymetrix and Illumina, a greater more variable set of

functional gene groups were used in addition within our gene lists. Hence, there is a degree of

variability in gene solutions, and it seems there is an interchangeable portion of our gene lists

in which a number of genes from uncorrelated functional groups of genes can be used to

achieve high performance in defining disease state.

Finally, we verified our gene lists for generalisability by retraining and evaluating on data

from a different manufacturer to which they were discovered in (Affymetrix Gene lists to

Illumina and Illumina Gene lists to Affymetrix). It is apparent that all gene lists tend to do

better on Affymetrix data, regardless of which set they were discovered on, which suggests

that the dataset, not the gene lists, is influencing performance. Hence, we have uncovered the

differentiating biological signatures underlying able to define bacterial and viral infections.

Conclusions

Our meta-analysis of Affymetrix and Illumina human blood infection data has revealed several panels of genes which are able to distinguish well between bacterial and viral infections. The difference in technology and gene coverage between Affymetrix and Illumina did not allow for a direct integration in our analysis. However, we were able to confirm that convergence was occurring independent of the technology, to both the same genes and the same functional groups of genes. This technology independent differentiable signal is learnable, and we demonstrated its presence by reconstructing the underlying regulatory gene network and overlaying models from the two datasets.

Acknowledgments

We thank all the contributing studies for generating and making publicly available their respective datasets. We also gratefully acknowledge DSTL (www.gov.uk/dstl) for providing support.

This work was also supported by the Chem-Bio Diagnostics program contract HDTRA1-12-D-0003-0023 from the Department of Defense Chemical and Biological Defense program through the Defense Threat Reduction Agency (DTRA).

570   ReferencesBibliography

1.   Shi Z, Gewirtz AT. Together Forever: Bacterial-Viral Interactions in Infection and Immunity.
Viruses. 2018;10(3):122.
2.   Chaplin DD. Overview of the immune response. The Journal of allergy and clinical
immunology. 2010;125(2 Suppl 2):S3-S23.
3.   Rock KL, Reits E, Neefjes J. Present Yourself! By MHC Class I and MHC Class II Molecules.
Trends Immunol. 2016;37(11):724-37.
4.   Yewdell JW, JR B. Mechanisms of Viral Interference with MHC Class I Antigen Processing and
Presentation. In: Annual Reviews Collection Bethesda (MD): National Center for Biotechnology
Information (US);. 2002.
5.   Manger ID, Relman DA. How the host 'sees' pathogens: global gene expression responses to
infection. Current Opinion in Immunology. 2000;12(2):215-8.
6.   Suarez NM, Bunsow E, Falsey AR, Walsh EE, Mejias A, Ramilo O. Superiority of transcriptional
profiling over procalcitonin for distinguishing bacterial from viral lower respiratory tract infections in
hospitalized adults. J Infect Dis. 2015;212(2):213-22.
7.   Sweeney TE, Wong HR, Khatri P. Robust classification of bacterial and viral infections via
integrated host gene expression diagnostics. Sci Transl Med. 2016;8(346):346ra91.
8.   Ramilo O, Allman W, Chung W, Mejias A, Ardura M, Glaser C, et al. Gene expression patterns
in blood leukocytes discriminate patients with acute infections. Blood. 2006;109(5):2066-77.
9.   Hu X, Yu J, Crosby SD, Storch GA. Gene expression profiles in febrile children with defined
viral and bacterial infection. Proceedings of the National Academy of Sciences. 2013;110(31):12792-
7.
10.   Nascimento EJM, Braga-Neto U, Calzavara-Silva CE, Gomes ALV, Abath FGC, Brito CAA, et al.
Gene expression profiling during early acute febrile stage of dengue infection can predict the disease
outcome. PloS one. 2009;4(11):e7892-e.
11.   Zaas AK, Chen M, Varkey J, Veldman T, Hero AO, Lucas J, et al. Gene Expression Signatures
Diagnose Influenza and Other Symptomatic Respiratory Viral Infections in Humans. Cell Host &
Microbe. 2009;6(3):207-17.
12.   Dawany N, Showe LC, Kossenkov AV, Chang C, Ive P, Conradie F, et al. Identification of a 251
gene expression signature that can accurately detect M. tuberculosis in patients with and without
HIV co-infection. PloS one. 2014;9(2):e89925-e.
13.   Lagani V, Karozou AD, Gomez-Cabrero D, Silberberg G, Tsamardinos I. A comparative
evaluation of data-merging and meta-analysis methods for reconstructing gene-gene interactions.
BMC Bioinformatics. 2016;17(5):S194.
14.   Akey JM, Biswas S, Leek JT, Storey JD. On the design and analysis of gene expression studies
in human populations. Nature Genetics. 2007;39(7):807-8.
15.   Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, et al. Adjustment of systematic
microarray data biases. Bioinformatics. 2004;20(1):105-14.
16.   Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using
empirical Bayes methods. Biostatistics. 2007;8(1):118-27.
17.   Trevino V, Falciani F. GALGO: an R package for multivariate variable selection using genetic
algorithms. Bioinformatics. 2006;22(9):1154-6.
18.   Breiman L. Random Forests. Machine Learning. 2001;45(1):5-32.
19.   Denil M, Matheson D, Freitas ND. Narrowing the Gap: Random Forests In Theory and In
Practice. In: Eric PX, Tony J, editors. Proceedings of the 31st International Conference on Machine
Learning; Proceedings of Machine Learning Research: PMLR; 2014. p. 665--73.
20.   Segal M. Machine Learning Benchmarks and Random Forest Regression. Technical Report,
Center for Bioinformatics & Molecular Biostatistics, University of California, San Francisco. 2003.
21.   Cawley GC, Talbot NLC. On Over-fitting in Model Selection and Subsequent Selection Bias in
Performance Evaluation. J Mach Learn Res. 2010;11:2079–107.

22.   Díaz-Uriarte R, Alvarez de Andrés S. Gene selection and classification of microarray data
using random forest. BMC Bioinformatics. 2006;7(1):3.
23.   Jiang H, Deng Y, Chen H-S, Tao L, Sha Q, Chen J, et al. Joint analysis of two microarray gene-
expression data sets to select lung adenocarcinoma marker genes. BMC Bioinformatics. 2004;5(1):81.
24.   Saeys Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics.
Bioinformatics. 2007;23(19):2507-17.
25.   Guyon I, Elisseeff A. An introduction to variable and feature selection. Journal of machine
learning research. 2003;3(Mar):1157-82.
26.   Bellman RE. Adaptive control processes: a guided tour: Princeton university press; 2015.
27.   Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists
using DAVID bioinformatics resources. Nature protocols. 2009;4(1):44-57.
28.   de la Fraga LG, Coello Coello CA. A Review of Applications of Evolutionary Algorithms in
Pattern Recognition. In: Wang PSP, editor. Pattern Recognition, Machine Intelligence and Biometrics.
Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 3-28.
29.   Uddin S, Khan A, Hossain ME, Moni MA. Comparing different supervised machine learning
algorithms for disease prediction. BMC Medical Informatics and Decision Making. 2019;19(1):281.
30.   Newman M. Networks: An Introduction. Oxford University Press. 2010.
31.   Rui X, Wunsch D. Survey of clustering algorithms. IEEE Transactions on Neural Networks.
2005;16(3):645-78.
32.   Su G, Kuchinsky A, Morris JH, States DJ, Meng F. GLay: community structure analysis of
biological networks. Bioinformatics. 2010;26(24):3135-7.
33.   Maier M, Luxburg Uv, Hein M. Influence of graph construction on graph-based clustering
measures. Proceedings of the 21st International Conference on Neural Information Processing
Systems; Vancouver, British Columbia, Canada: Curran Associates Inc.; 2008. p. 1025–32.
34.   Wang X, Lin Y, Song C, Sibille E, Tseng GC. Detecting disease-associated genes with
confounding variable adjustment and the impact on genomic meta-analysis: With application to
major depressive disorder. BMC Bioinformatics. 2012;13(1):52.
35.   Pearson K. LIII. On lines and planes of closest fit to systems of points in space. The London,
Edinburgh, and Dublin Philosophical Magazine and Journal of Science. 1901;2(11):559-72.
36.   Wright MN, Ziegler A. ranger: A Fast Implementation of Random Forests for High
Dimensional Data in C++ and R. 2017. 2017;77(1):17.
37.   Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference,
and prediction: Springer Science & Business Media; 2009.
38.   Diaz-Uriarte R. GeneSrF and varSelRF: a web-based tool and R package for gene selection
and classification using random forest. BMC Bioinformatics. 2007;8(1):328.
39.   Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R, et al. ARACNE:
an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context.
BMC bioinformatics. 2006;7 Suppl 1(Suppl 1):S7-S.
40.   Boucher B, Jenna S. Genetic interaction networks: better understand to better predict.
Frontiers in genetics. 2013;4:290.
41.   Mani R, St.Onge RP, Hartman JL, Giaever G, Roth FP. Defining genetic interaction.
Proceedings of the National Academy of Sciences. 2008;105(9):3461-6.
42.   Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software
environment for integrated models of biomolecular interaction networks. Genome research.
2003;13(11):2498-504.
43.   Newman ME, Girvan M. Finding and evaluating community structure in networks. Physical
review E. 2004;69(2):026113.
44.   Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, et al. The DAVID Gene
Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze
large gene lists. Genome Biol. 2007;8(9):R183-R.

45.   Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin
Rheumatol. 2013;25(2):248-53.

46.   Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of
host defenses. Annu Rev Immunol. 2014;32:513-45.

47.   McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease.
Nat Rev Immunol. 2015;15(2):87-103.

48.   Kyogoku C, Smiljanovic B, Grun JR, Biesen R, Schulte-Wrede U, Haupl T, et al. Cell-specific
type I IFN signatures in autoimmunity and viral infection: what makes the difference? PLoS One.
2013;8(12):e83776.

49.   Singh H, Samani D, Nambiar N, Ghate MV, Gangakhedkar RR. Prevalence of MMP-8 gene
polymorphisms in HIV-infected individuals and its association with HIV-associated neurocognitive
disorder. Gene. 2018;646:83-90.

50.   Jans J, Unger WWJ, Vissers M, Ahout IML, Schreurs I, Wickenhagen A, et al. Siglec-1 inhibits
RSV-induced interferon gamma production by adult T cells in contrast to newborn T cells. Eur J
Immunol. 2018;48(4):621-31.

51.   Hammonds JE, Beeman N, Ding L, Takushi S, Francis AC, Wang JJ, et al. Siglec-1 initiates
formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of
HIV-1. PLoS Pathog. 2017;13(1):e1006181.

52.   Demaret J, Venet F, Plassais J, Cazalis M-A, Vallin H, Friggeri A, et al. Identification of CD177
as the most dysregulated parameter in a microarray study of purified neutrophils from septic shock
patients. Immunology Letters. 2016;178:122-30.

53.   Stroncek DF. Neutrophil-specific antigen HNA-2a, NB1 glycoprotein, and CD177. Curr Opin
Hematol. 2007;14(6):688-93.

54.   Dietterich TG. Approximate Statistical Tests for Comparing Supervised Classification Learning
Algorithms. Neural Computation. 1998;10(7):1895-923.

55.   Jin T, Xu X, Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine.
2008;44(1):1-8.

56.   Das A, Guha P, Sen D, Chaudhuri TK. Role of toll like receptors in bacterial and viral diseases
– A systemic approach. Egyptian Journal of Medical Human Genetics. 2017;18(4):373-9.

57.   Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.
Blood. 2011;117(14):3720-32.

58.   Barnes M, Freudenberg J, Thompson S, Aronow B, Pavlidis P. Experimental comparison and
cross-validation of the Affymetrix and Illumina gene expression analysis platforms. Nucleic acids
research. 2005;33(18):5914-23.

59.   Rosebeck S, Leaman DW. Mitochondrial localization and pro-apoptotic effects of the
interferon-inducible protein ISG12a. Apoptosis : an international journal on programmed cell death.
2008;13(4):562-72.

60.   Liu N, Zuo C, Wang X, Chen T, Yang D, Wang J, et al. miR-942 decreases TRAIL-induced
apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget. 2014;5(13):4959-71.

61.   Gytz H, Hansen MF, Skovbjerg S, Kristensen AC, Horlyck S, Jensen MB, et al. Apoptotic
properties of the type 1 interferon induced family of human mitochondrial membrane ISG12
proteins. Biology of the cell. 2017;109(2):94-112.

62.   Mar KB, Rinkenberger NR, Boys IN, Eitson JL, McDougal MB, Richardson RB, et al. LY6E
mediates an evolutionarily conserved enhancement of virus infection by targeting a late entry step.
Nat Commun. 2018;9(1):3603.

63.   Saitoh S, Kosugi A, Noda S, Yamamoto N, Ogata M, Minami Y, et al. Modulation of TCR-
mediated signaling pathway by thymic shared antigen-1 (TSA-1)/stem cell antigen-2 (Sca-2). Journal
of immunology (Baltimore, Md : 1950). 1995;155(12):5574-81.

64.   Meng F, Lowell CA. Lipopolysaccharide (LPS)-induced macrophage activation and signal
transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. The Journal of experimental
medicine. 1997;185(9):1661-70.

65.   Tang BM, Shojaei M, Parnell GP, Huang S, Nalos M, Teoh S, et al. A novel immune biomarker
IFI27 discriminates between influenza and bacteria in patients with suspected respiratory infection.
The European respiratory journal. 2017;49(6).
66.   Andres-Terre M, McGuire HM, Pouliot Y, Bongen E, Sweeney TE, Tato CM, et al. Integrated,
Multi-cohort Analysis Identifies Conserved Transcriptional Signatures across Multiple Respiratory
Viruses. Immunity. 2015;43(6):1199-211.
67.   Tough DF. Type I interferon as a link between innate and adaptive immunity through
dendritic cell stimulation. Leuk Lymphoma. 2004;45(2):257-64.
68.   Hertzog PJ, O'Neill LA, Hamilton JA. The interferon in TLR signaling: more than just antiviral.
Trends in immunology. 2003;24(10):534-9.
69.   Kovarik P, Castiglia V, Ivin M, Ebner F. Type I Interferons in Bacterial Infections: A Balancing
Act. Frontiers in immunology. 2016;7(652).

Supporting information

S1 Appendix. Pre-processing.

S1 Fig. Affymetrix Interaction Network. Affymetrix recovered interaction network at first

level of clustering. Selected model genes are highlighted.

S1 Table. Model Gene Selection Frequency. Affymetrix and Illumina model selected genes

with relative frequency of selection (genes with greater than 5% aggregated inclusion across

all search procedures).

S2 Appendix. Biomarker Search.

S2 Fig. Illumina Interaction Network. Illumina recovered interaction network at first level

of clustering. Selected model genes are highlighted.

S2 Table. Highly selected gene clusters from Affymetrix and Illumina interaction

network. Table containing the genes from the 4 highly model selected Illumina clusters, and

5 highly model selected gens from the Affymetrix clusters.

S3 Appendix. Inferred Interaction Networks.

S3 Table. Out-sample results of gene lists. The out-sample results from running Affymetrix

derived gene lists on the Illumina data, and the Illumina derived gene lists on the Affymetrix

data